Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MetXia gene therapy - Oxford BioMedica

Drug Profile

MetXia gene therapy - Oxford BioMedica

Alternative Names: MetXia; MetXia-MG; MetXia-P450; MetXia-VM; P450-GDEPT

Latest Information Update: 18 Sep 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Oxford BioMedica
  • Class Gene therapies
  • Mechanism of Action Cytochrome P-450 enzyme system modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Pancreatic cancer
  • Discontinued Breast cancer; Malignant melanoma; Ovarian cancer

Most Recent Events

  • 29 Aug 2007 MetXia gene therapy is still in phase II trials for pancreatic cancer in the UK
  • 24 Mar 2005 A clinical study has been added to the adverse events and pharmacodynamics section
  • 16 Feb 2004 Phase-II clinical trials in Pancreatic cancer in United Kingdom (intratumoural)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top